Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 300
Healthy volunteers: no

Brief summary:
The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine. The study will last about 31 weeks for each participant.

Detailed description:

Arms:
arm 1: 1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses. arm 2: Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.

Interventions: intervention 1: Dulaglutide intervention 2: Placebo intervention 3: Insulin Glargine intervention 4: Metformin
Intervention descriptions: intervention 1: Administered SQ intervention 2: Administered SQ intervention 3: Administered SQ intervention 4: Administered orally

Protocol document: